With more than 30 years of experience in life sciences, Wendy has a strong record of success in financial, operational and corporate development. Wendy has led many companies through various stages of development and commercialization. Over the last seven years she has served as a life science advisor, often in an interim executive capacity, to several emerging growth companies as they approached and successfully accomplished IPO, a transformative acquisition or merger or first-time commercialization.

Most recently, she has served as the interim Chief Financial Officer (CFO) for Akari Therapeutics (NASDAQ: AKTX) and for Renovacor (NYSE: RCOR) and FerGene, all companies advancing targeted therapeutics through the clinical pipeline to commercialization. Previously, she was Chief Operating and Financial Officer of Centinel Spine, a global commercial spinal implant developer and manufacturer. Prior to Centinel, she held several public and private company CFO roles including: Camber Spine, Nuron Biotech, Quench USA, Globus Medical and Kensey Nash Corporation. She started her career in accounting at Deloitte & Touche, LLP.

Wendy currently serves on the board of directors of EyePoint Pharmaceuticals (NASDAQ:EYPT) and Imvax, Inc. and has previously served on multiple public and private life science company boards over the last 20 years. Wendy received a B.S. in accounting from Philadelphia College of Textiles and Science and is a licensed CPA. She is also an appointed Board Leadership Fellow of the National Association of Corporate Directors (NACD).

Ellen K. Forest most recently served as a strategic human resources advisor on an interim basis for two early-stage biotechnology companies. Prior to that, she was Chief Human Resources Officer at Yumanity Therapeutics (now Kineta, Inc.), where she led the company’s human resources function and developed a strategic HR vision aligned with the company’s overall mission and goals.

Before joining Yumanity, Ms. Forest was Senior Vice President and Head of Human Capital at Cogen Immune Medicine (now Repertoire Immune Medicines), a biotech firm focused on immune modulation therapeutics. Earlier in her career, she served as Vice President and Head of Human Resources at Merrimack Pharmaceuticals, a publicly traded company, where she directed human resources strategy across organizational leadership, talent management, change initiatives, and corporate culture.

Ms. Forest also held senior HR roles at Baxalta (acquired by Shire), Partners HealthCare (a non-profit healthcare system), and TA Associates, a global private equity firm, where she gained broad experience across the life sciences and investment sectors.

Ms. Forest holds an M.S. in Human Resources Management and a B.S. in Business from Emmanuel College and serves as a member of several human resources organizations.

Tom, who joined the flock in May of 2021 as our Chief Commercial Officer, has deep passion for patients and experience across multiple commercial roles in both rare diseases and oncology. Most recently, Tom served as Chief Commercial Officer at Gamida Cell, leading a high-growth, fast paced oncology cell therapy organization and establishing a culture of transparency, trust and empowerment. Prior to his tenure at Gamida Cell, Tom served in a variety of leadership roles at Atara Biotherapeutics, Navidea Biopharmaceuticals and Algeta U.S. where he led the successful commercial build-out and launch of Xofigo^®. Before Algeta, he held various commercial leadership positions at Dendreon. Tom began his pharmaceutical career at Eli Lilly where he held several positions of increasing responsibility and participated in the global launch of Cymbalta^®. Tom earned a B.A. in Business Administration and Marketing from Western State College.

David Meek brings over 30 years of experience in the biopharmaceutical industry, having held multiple leadership roles across a range of organizations. He has served as CEO of both public and private biopharma companies, including Mirati Therapeutics, FerGene, and Ipsen.

Before joining Ipsen, David held executive roles such as Executive Vice President and President of Oncology at Baxalta, and Chief Commercial Officer at Endocyte. He also served in global and general management roles at Novartis Pharmaceuticals and Novartis Oncology, after beginning his career at Johnson & Johnson’s Janssen Pharmaceuticals.

David currently serves on the boards of several public biotech companies, including Sobi, uniQure N.V., and Cullinan Therapeutics. He previously served on the boards of Fusion Pharmaceuticals and Entasis Therapeutics until their respective acquisitions. Additionally, he is a board member of the University of Southern California Mann School of Pharmacy and Pharmaceutical Sciences.

He has also contributed to the industry through his service on the boards of the Pharmaceutical Research and Manufacturers of America (PhRMA) and the European Federation of Pharmaceutical Industries and Associations (EFPIA). A decorated commissioned officer in the U.S. Army, David served on active duty and achieved the rank of captain. He is a graduate of the University of Cincinnati.

Debasish Roychowdhury, MD is a medical oncologist/hematologist. He has over 25 years of experience in the pharmaceutical and biotech industry as well as many years of patient care, academic research and teaching experience. He has been part of the development and approval of 13 drugs.

He is the co-founder of Partner Therapeutics, a commercial biotech based in Lexington, MA. He has served as the CMO at Seragon and Ra Pharmaceuticals and served as a consultant for other biotech companies and academic centers. Prior to Seragon, Dr. Roychowdhury served as the Senior Vice President and Head of the Global Oncology Division at Sanofi, the Vice President for Clinical Development at GlaxoSmithKline, and directed the Oncology global regulatory group at Eli Lilly and Company.

Prior to his role in industry, he served as a faculty member at the University of Cincinnati and the VA Medical Center. Dr. Roychowdhury is a member of the Board of Directors of multiple biotech companies and serves on multiple scientific advisory boards. He is on the faculty of the Department of Biological Engineering, MIT, Cambridge.

Dr. Roychowdhury trained at the All India Institute of Medical Sciences, New Delhi, University of Illinois, Chicago and University of California, San Francisco.